Seaport Therapeutics begins phase 2b trial of GlyphAllo for major depression - PharmaTimes First patient dosed in BUOY-1 study targeting MDD with or without anxious distress

#mentalhealth #SeaportTherapeutics #phase2btrial #GlyphAllo #BUOY1study #MDD #anxiousdistress #allopregnanolone #majordepressivedisorder #allopregnanolone #rapidantidepressant #anxiolytic #HAMD17 #depressionratingscale #CNSclinicaltrials #depression #anxiety
pharmatimes.com/news/seaport...